Novartis Venture Fund and Partners Innovation Fund both took part in a round that will fund the first human trials for the company's gene therapies.
US-based genetic medicine developer Akouos secured $50m yesterday in a series A round featuring corporate venturing representatives of healthcare provider Partners Healthcare and pharmaceutical firm Novartis.
Partners Innovation Fund and Novartis Venture Fund invested alongside venture capital firms 5AM Ventures and New Enterprise Associates (NEA), which co-led the round, Sofinnova Ventures and RA Capital Management.
Founded in 2016, Akouos is developing precision genetic medicines intended to treat sensorineural hearing loss, which is caused by damage to the inner ear’s sensory…
